Mishra, R. R. Et Al. 2018. Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer. CLINICAL CANCER RESEARCH , vol.24, no.8 , 1987-2001.

Mishra, R. R., Belder, N., Ansari, S. A., Kayhan, M., Bal, H., Raza, U., ... Ersan, P. G.(2018). Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer. CLINICAL CANCER RESEARCH , vol.24, no.8, 1987-2001.

Mishra, Rasmi Et Al. "Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer," CLINICAL CANCER RESEARCH , vol.24, no.8, 1987-2001, 2018

Mishra, Rasmi R. Et Al. "Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer." CLINICAL CANCER RESEARCH , vol.24, no.8, pp.1987-2001, 2018

Mishra, R. R. Et Al. (2018) . "Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer." CLINICAL CANCER RESEARCH , vol.24, no.8, pp.1987-2001.

@article{article, author={Rasmi R. Mishra Et Al. }, title={Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer}, journal={CLINICAL CANCER RESEARCH}, year=2018, pages={1987-2001} }